Product image of Imipenem + Cilastatina Aurovitas (Cilastatin Sodium, Imipenem Monohydrate) supplied by GNH India

Imipenem + Cilastatina Aurovitas

Active Ingredient:
Cilastatin Sodium, Imipenem Monohydrate
Origin:
EU

Imipenem + Cilastatina Aurovitas (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem, the active ingredient in Imipenem + Cilastatina Aurovitas, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum activity against Gram‑positive and Gram‑negative bacteria and is employed to treat serious infections such as complicated intra‑abdominal infections, urinary tract infections, hospital‑acquired pneumonia, meningitis, and septicemia in hospitalized patients.

GNH India supplies Imipenem + Cilastatina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics and specialized care facilities worldwide.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Imipenem/cilastatin is a carbapenem antibiotic used to treat severe bacterial infections across several organ systems.
  • Complicated intra‑abdominal infection: rapid bacterial eradication leading to clinical improvement.
  • Complicated urinary tract infection: eradication of uropathogens and resolution of infection.
  • Hospital‑acquired pneumonia: effective against resistant pathogens causing lower respiratory infection.
  • Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.
  • Septicemia: broad‑spectrum coverage for bloodstream infections caused by susceptible organisms.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting the final stages of bacterial cell wall synthesis, which leads to cell lysis. Cilastatin, co‑administered, inhibits renal dehydropeptidase I, preventing enzymatic degradation of imipenem in the kidneys and thereby extending its antibacterial activity.

Side Effects

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal discomfort.
  • Diarrhea: may be watery and self‑limiting.
  • Rash: skin erythema or pruritus.
  • Headache: transient cephalic pain.
  • Elevated liver enzymes: mild transaminase increase.
  • Injection site pain: local discomfort during infusion.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment or high doses.
  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Clostridioides difficile colitis: antibiotic‑associated severe diarrhea.
  • Neutropenia: marked reduction in neutrophil count.
  • Renal failure: worsening kidney function in susceptible individuals.

Precautions & Warnings

  • Use imipenem/cilastatin with caution in specific clinical situations.
  • Renal function: adjust dosing in patients with impaired renal clearance.
  • Allergy: avoid in individuals with known hypersensitivity to β‑lactam antibiotics or cilastatin.
  • Seizure risk: monitor patients with central nervous system disorders or receiving high doses.
  • Drug interactions: review concomitant medications that may lower seizure threshold.
  • Pregnancy: consider only if potential benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Imipenem/cilastatin may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Valproic acid: may reduce serum valproate levels, increasing seizure risk.
  • CNS depressants: concurrent use can lower seizure threshold.
  • Renal dehydropeptidase inhibitors: may interfere with cilastatin activity.

Moderate Interactions (Monitor Closely)

  • Aminoglycosides: additive nephrotoxicity potential.
  • Loop diuretics: may increase risk of ototoxicity.
  • Anticoagulants: possible enhancement of anticoagulant effect, requiring INR monitoring.

Frequently Asked Questions

Imipenem + Cilastatina Aurovitas is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, meningitis, and septicemia. It is administered intravenously in hospitalized patients who require broad‑spectrum antimicrobial coverage.

Imipenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, which prevents the cross‑linking of peptidoglycan strands and leads to bacterial lysis. Cilastatin, co‑formulated, blocks renal dehydropeptidase I, protecting imipenem from enzymatic degradation and extending its antibacterial activity.

The dosage of Imipenem + Cilastatina Aurovitas is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals should follow local prescribing guidelines and adjust the dose as needed.

Safety data for Imipenem + Cilastatina Aurovitas in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient.

To request Imipenem + Cilastatina Aurovitas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imipenem combined with cilastatin offers a broad spectrum of activity similar to other carbapenems such as meropenem or ertapenem, but the addition of cilastatin protects imipenem from renal degradation, potentially allowing higher plasma concentrations. Choice among carbapenems depends on local resistance patterns, pharmacokinetic considerations, and clinician preference.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, inspect the vial for particulate matter and discoloration. Follow aseptic techniques during preparation and infusion.

Imipenem + Cilastatina is given as an intravenous infusion, typically diluted in compatible IV fluids. The infusion rate and duration are determined by the prescribing clinician, taking into account the infection type, patient renal function, and tolerability.

Serious adverse events include seizures, especially in patients with renal impairment or high doses, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, neutropenia, and worsening renal function. Prompt medical evaluation is required if any of these occur.

Patients with a known hypersensitivity to imipenem, other β‑lactam antibiotics, or cilastatin should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting drugs that lower the seizure threshold.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin Sodium, Imipenem Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT